Publications

Publications

Filter Results: (175) Arrow Down
Filter Results: (175) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 9 of 175 Results
  • 20 Sep 2016
  • First Look

September 20, 2016

since it was started, with no therapeutic product available in the foreseeable future, Kaplan is considering whether it is time to change the company's business model. Purchase this case:... View Details
Keywords: Sean Silverthorne
  • 01 Dec 2013
  • News

Curing Health Care

products. Stock predicts that the development pace for personalized therapeutics and preventive diagnostics will pick up speed, thanks to the beneficial add-on effects derived from identifying more and more biomarkers for particular... View Details
Keywords: Ambulatory Health Care Services; Health, Social Assistance; Management; Colleges, Universities, and Professional Schools; Educational Services
  • 01 Aug 2017
  • First Look

First Look at New Research and Ideas, August 1

drugs (chemically-synthesized, “small-molecule” drugs) face price competition from generic drugs after patent expiration, biosimilars—biologic drugs that have been shown to be therapeutically equivalent to an already approved original... View Details
Keywords: Sean Silverthorne
  • 11 Apr 2017
  • First Look

First Look at New Research, April 11

treated with unproductive therapies while more easily uncovering therapeutic signals. However, such research initiatives alone will not deliver new medicines to patients in the absence of strong incentives to bring new products to market.... View Details
  • 05 Feb 2013
  • First Look

First Look: Feb. 5

The FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine. The FDA's approval of such drugs, along with companion diagnostics, suggested a... View Details
Keywords: Sean Silverthorne
  • 19 May 2009
  • First Look

First Look: May 19, 2009

the significance levels are lower.   Cases & Course MaterialsAdnexus Therapeutics, Inc.: Considering the Exit Harvard Business School Case 609-015 Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology... View Details
Keywords: Martha Lagace
  • 15 Jan 2019
  • First Look

New Research and Ideas, January 15, 2019

forthcoming American Journal of Therapeutics Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses By: Weitzman, Rachel E., Ariel Dora Stern, and Daniel B. Kramer Abstract—No abstract... View Details
Keywords: Dina Gerdeman
  • 01 Feb 1997
  • News

Shaping the Future of Business: Entrepreneurial Evolution at HBS

a thriving organization of significant scale. Gordon M. Binder (MBA '62) played a key role in just such a transition at Amgen, which now ranks as the largest biotechnology firm in the world. A California-based firm that discovers, develops, manufactures, and markets... View Details
Keywords: Nancy O. Perry and Susan Young; profiles by Garry Emmons
  • 08 Jun 2010
  • First Look

First Look: June 8

uncertainty of commercial partners' interest in the therapeutic approach, and the constrained donor-based fundraising environment. Purchase this case:http://cb.hbsp.harvard.edu/cb/product/610074-PDF-ENG Data.gov Karim R. Lakhani, Robert... View Details
Keywords: Martha Lagace
  • 28 Apr 2009
  • First Look

First Look: April 28, 2009

Industry Location and International Regulatory Variation Author:Arthur A. Daemmrich Publication:Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, 271-290. Berlin, Germany: Max Planck... View Details
Keywords: Martha Lagace
  • Web

Print View - Course Catalog

enhanced, aging could be reversed, new forms of life created, and new custom designed materials could be grown rather than manufactured. Companies like Verve Therapeutics announced the first human trials of a single shot cure for all... View Details